Categories
Procedure
Organizational Structure
Merit Medical Systems, Inc. (“Merit Medical”), as parent company, issues this statement on behalf of its subsidiary, Merit Medical UK Limited, relevant to UK Action Note PPN 06/21.
Merit Medical Systems, Inc. is a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. We strive to be the most customer-focused company in healthcare. Each day we are determined to make a difference by understanding our customers’ needs and innovating and delivering a diverse range of products that improve the lives of people and communities throughout the world. We believe that long-term value is created for our customers, employees, shareholders, and communities when we focus outward and are determined to deliver exceptional customer experience.
For more information, please visit www.merit.com.
Commitment to Achieving Net-Zero
Merit Medical UK Limited is committed to achieving net-zero emissions by 2050.
Emissions Reduction Targets
Merit Medical has adopted the following greenhouse gas reduction targets. Our targets are reviewed and approved by the Governance and Sustainability Committee of our Board of Directors.
- Near-Term Target: Merit Medical commits to reducing absolute Scope 1 and 2 GHG emissions by 40% by 2030 from a 2020 baseline year.
To support our Scope 1 and 2 near-term target, Merit Medical commits to use 50% or more renewable electricity globally by 2030. - Long-Term Target: Merit Medical commits to reduce absolute Scopes 1 and 2 GHG emissions by 65% by 2050 from the 2020 baseline year.
Baseline Emissions Footprint
Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.
| Baseline Year: 2020 (Scope 1 + 2); 2023 (Scope 3) | |
|---|---|
| Additional Details relating to the Baseline Emissions calculations. | |
|
All emissions are calculated using an operational control boundary, in accordance with the Greenhouse Gas Protocol corporate standard (“GHG Protocol”) and are inclusive of UK operations for Merit Medical. Merit Medical’s required Scope 3 categories for the UK were first calculated in 2023, resulting in a different baseline year than Scope 1 and 2. In 2025, Merit Medical underwent a rebaselining exercise to account for acquisitions and to increase alignment with internationally recognized best practices, such as the Greenhouse Gas (GHG) Protocol. As a result, we have restated baseline figures to reflect the improved accuracy. These restatements are part of our commitment to transparency and continuous improvement in our carbon reporting practices. |
|
| Baseline year emissions: 2020 (Scope 1 + 2); 2023 (Scope 3) | |
| EMISSIONS | TOTAL (tCO2e) |
| Scope 1 | 61.45 |
| Scope 2 | 38.60 |
| Scope 3 |
6,000 The total of 6,000 includes emissions associated with Scope 3 categories: 1- Purchased goods and services Emissions from 7 – Commuting have not yet been calculated |
| Total Emissions | 6,100.05 tCO2e |
UK Current Emissions Reporting
| Reporting Year: 2025 | |
|---|---|
|
All emissions are calculated using an operational control boundary, in accordance with the Greenhouse Gas Protocol corporate standard (“GHG Protocol”) and are inclusive of UK operations for Merit Medical Systems, Inc. *Merit’s 2025 Scope 3 emissions will not be updated until Q3 2026. Therefore, Scope 3 emissions shown are from 2024. This plan will be updated when Scope 3 calculations for 2025 have been completed. |
|
| EMISSIONS | TOTAL (tCO2e) |
| Scope 1 | 71.68 |
| Scope 2 | 42.03 |
| Scope 3 |
6,340.50* The total of 6,340.50 includes emissions associated with Scope 3 categories: 1- Purchased Goods and Services Emissions from 7 – Commuting have not yet been calculated |
| Total Emissions | 6,454.21 tCO2e |
Progress Toward Emission Reduction Targets
As stated above, Merit Medical committed to reducing absolute Scope 1 and 2 Emissions by 40% by 2030 and 65% by 2050. From its baseline year of 2020, Merit Medical UK Limited has increased scope 1 and 2 emissions by 13.7%. This is primarily due to the rebaselining of its 2020 emissions to account for previously omitted fugitive emissions from use of refrigerant gases.
Carbon Reduction Projects
Moving forward, Merit Medical hopes to implement or continue the following projects within our UK Operations:
- Source Renewable Energy Guarantees of Origin (REGOs)
- Support Merit Medical’s Smart Shipping initiative which aims to reduce unnecessary packaging associated with its products
- Implement energy reduction programs within our UK warehousing operations such as movement to 100% LED lighting.
- Improved accuracy of Scopes 1, 2, and 3 emissions in 2026
Declaration and Sign Off
This Carbon Reduction Plan has been completed in accordance with PPN06/21 and associated guidance and reporting standard for Carbon Reduction Plans.
Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard1 and uses the appropriate government emission conversion factors for greenhouse gas company reporting2.
Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard3.
This Carbon Reduction Plan has been reviewed and signed off by the Vice President, Environment, Social & Governance for Merit Medical Systems, Inc.
Signed on behalf of the Supplier:
Alisha Jerauld
Vice President, Environment, Social and Governance
Date: 30 June 2026
1 https://ghgprotocol.org/corporate-standard
2 https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting
3 https://ghgprotocol.org/standards/scope-3-standard